Factors influencing adherence to intravesical instillation therapies for non-muscle-invasive bladder cancer: a scoping review protocol Authors: Lisbeth Roesen Leinum, Bente Thoft Jensen, Susanne Vahr Lauridsen Published: 2026 ABSTRACT AbstractIntroductionNon-muscle-invasive bladder cancer is often treated with repeated weekly intravesical instillations of chemotherapy or immunotherapy. The number of instillations received influences the risk of recurrence and progression; thus, treatment completion is crucial. However, previous research indicates that nearly half of patients do not adhere to treatment for various reasons. This scoping review aims to define the concept of treatment adherence to intravesical instillation therapies and identify and map the factors that influence treatment adherence in intravesical instillation therapies.Methods and analysisThis scoping review will adhere to the Joanna Briggs Institute’s Manual for Evidence Synthesis and will be reported in accordance with the PRISMA Extension for Scoping Reviews. A comprehensive search strategy will be employed to guide the literature search across databases, including MEDLINE, Embase, Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Central Register of Controlled Trials.We will include studies on intravesical instillation therapies with BCG or Mitomycin C for non-muscle-invasive bladder cancer, as well as studies that describe factors influencing patients’ adherence to treatment. Screening of abstracts and full texts, as well as data charting, will be performed independently by two researchers using the Covidence software. We will collect and chart data concerning characteristics of the source and setting, treatment specifics, reasons for non-adherence and any factors that affect adherence.We will summarise each included source and present the identified factors in a narrative synthesis. Furthermore, we will describe how the results inform the review objective.Ethics and disseminationEthical approval is not required for this scoping review, as all data have been published. The findings of the scoping review will be disseminated in a scientific publication and widely presented to researchers, healthcare professionals and patients. STRENGTHS AND LIMITATIONS OF THIS STUDY This scoping review will be conducted and reported according to methodological guidelines for scoping reviews, ensuring rigour and transparency This scoping review will be conducted and reported according to methodological guidelines for scoping reviews, ensuring rigour and transparency Broad search criteria will be applied, and limiting the search outcome by additional search terms will be avoided Broad search criteria will be applied, and limiting the search outcome by additional search terms will be avoided Grey literature sources will be included, and national guidelines on the topic will be sought. Grey literature sources will be included, and national guidelines on the topic will be sought. Regional databases such as CKNI and LILACS will not be searched due to language and resource constraints. Thus, some evidence may be missed. Regional databases such as CKNI and LILACS will not be searched due to language and resource constraints. Thus, some evidence may be missed. Introduction Bladder cancer is the fifth most frequently diagnosed cancer in Europe,1 with approximately 2000 new Danish cases per year,2 imposing major healthcare costs and a significant burden on patients related to treatment and surveillance regimes with multiple procedures and hospital visits. Bladder cancer is classified as either non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of cases, or muscle-invasive bladder cancer (25%). The first line of treatment for NMIBC involves the surgical removal of tumours followed by repeated cystoscopies, several intravesical instillations or cystectomy.3 There is an increasing demand for using Patient Reported Outcome Measures (PROMs) in cancer treatment in Europe,4 accompanied by a preference for minimally invasive procedures whenever feasible. This has led to a greater emphasis on the benefits of instillation therapies for preventing or delaying the progression of NMIBC.5 Intravesical instillation therapy has been used for decades, and the most common treatment choices are intravesical chemotherapy with Mitomycin (MMC) and immunotherapy with a live strain of BCG.3 Intravesical instillation involves the slow induction of therapeutic fluids into the bladder, allowing them to remain in place for a dwell time of 1–2 hours before being drained or voided. The procedure is performed by nurses and is designed to expose the bladder’s tissue to the therapeutic solution. It facilitates targeted drug delivery to the urothelium while minimising systemic side effects compared with oral or parenteral administration.6 The number of instillations received is associated with the risk of recurrence.3 7 Therefore, it is essential that patients complete their treatment. For optimal efficacy, BCG should be administered as an induction with 6 weekly instillations, followed by maintenance with 3 weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months.8 Unfortunately, treatments have significant side effects, with 47% of patients experiencing adverse effects9 10 and 46% of patients withdrawing from BCG treatment within the first year and 90% before completion.11 Factors influencing treatment adherence include side effects10 and a significant treatment burden due to the frequency of hospital visits, unmet needs and psychological distress,12 as well as socioeconomic factors such as expenditure per visit, travel mode13 and inability to take time off work.14 Suboptimal treatment adherence highlights the need for further exploration regarding factors influencing adherence to intravesical instillations. Moreover, the reasons for withdrawal have not been examined in a comprehensive or systematic manner. Key risk factors for bladder cancer include increasing age, being male, smoking, occupational exposure to harmful substances, a history of urinary tract infections, chronic indwelling catheters and pelvic radiation, as well as certain medications.15 Tobacco smoking and exposure to harmful carcinogens in occupations such as chimney sweeps, hairdressers, printers and firefighters are linked to socioeconomic elements such as educational level and disposable income.16 17 As a result, health inequality presents a significant challenge in the diagnosis and treatment of bladder cancer, due to a higher incidence among individuals with low socioeconomic status,18 19 a greater likelihood of being diagnosed with high-risk20 or late-stage disease,21 and a reduced overall survival.21 22 Inequalities in health can arise at various stages of the disease due to delayed contact and diagnosis,23 delayed treatment,14 21 the presence of comorbidities that complicate treatment options and non-compliance.24 In this scoping review, we will explore the existing evidence on factors influencing patient adherence to intravesical instillation therapies for treating non-muscle-invasive bladder cancer. We conducted a preliminary search in PROSPERO, the Cochrane Database of Systematic Reviews and JBI Evidence Synthesis and identified no systematic or scoping reviews on the topic. Therefore, this scoping review aims to map the factors affecting treatment adherence in intravesical instillation treatments. Aim and research question We aim to map how the concept of treatment adherence to intravesical instillation therapies is defined in the literature, and the demographic, socioeconomic, physical, psychological and social factors reported to influence adherence to intravesical instillation therapies aimed at treating non-muscle-invasive bladder cancer by answering the following research question: How is treatment adherence defined? How is treatment adherence defined? What factors influence patients’ adherence to intravesical instillation therapies to treat non-muscle invasive bladder cancer? What factors influence patients’ adherence to intravesical instillation therapies to treat non-muscle invasive bladder cancer? Methods and analysis We plan to conduct a scoping review to comprehensively cover the factors influencing patient adherence to intravesical instillation therapies by mapping and reporting the literature.25 26 Through a scoping review, we can systematically collate, review and summarise the complex and potentially heterogeneous evidence concerning the key factors influencing treatment adherence, including both quantitative and qualitative study designs. Protocol and registration This scoping review protocol was developed with inspiration from the JBI guidance for developing scoping review protocols.27 The methods, objectives and inclusion criteria for the scoping review were prespecified before initiation and are documented in this paper. In the review, we will follow a rigorous methodology as outlined in the JBI Manual for Evidence Synthesis.28 The review will be reported according to the guideline for Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR).29 Any amendments to the protocol will be documented and reported in the final review Eligibility criteria The search terms were developed according to the Patient, Concept and Context (PCC) Framework28 and reflect the inclusion criteria. Patients We will include sources of evidence, including adult patients above 18 years of age diagnosed with NMIBC. Included patients will be eligible for intravesical instillation therapies with immunotherapy or chemotherapy to treat NMIBC. Specifically, we will include studies describing intravesical instillations of BCG or Mitomycin C. Concept The core concept is patients’ treatment adherence. We will extract how treatment adherence is defined and include studies that address factors influencing adherence. Relevant factors may stem from demographic, psychological, physical or social issues. Context The repeated instillation of intravesical therapies is usually performed in urological outpatient clinics, and no limitations related to the context will be applied. The included studies were published in 1967 or later, when Mitomycin C was first used for bladder cancer treatment.30 BCG was introduced in bladder cancer treatment in a small clinical trial published in 1976.31 We will allow the inclusion of all sources of evidence, including randomised and non-randomised studies, prospective and retrospective cohort studies, cross-sectional studies, case studies, qualitative studies and reviews, provided they meet the above-mentioned inclusion criteria. Grey literature and guidelines will also be included if appropriate. Search strategy and information sources A three-step approach will be used in this scoping review to ensure full coverage. The initial search was developed in MEDLINE Ovid through consultation with and in collaboration with a research librarian at the same hospital as the first author. The search was adopted for use in the additional databases Embase Ovid, Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Central Register of Controlled Trials. Relevant index terms and text words will be identified, and the searches will be adapted accordingly. The overall topic of intravesical instillation therapies for treating NMIBC was searched by building a search strategy including appropriate subject headings and terms analogous to NMIBC, ensuring a broad capture of relevant papers. These keywords are separated by the Boolean operator ‘OR’. Subject headings and search terms analogous to intravesical therapies are also combined by ‘OR’, and finally, the search terms on the disease and treatment are combined by the Boolean operator ‘AND’. This search was combined with keywords related to adherence, compliance and treatment completion; however, this resulted in a very narrow and limited number of results.32 Therefore, we will use a broader search string and select studies addressing adherence to treatment during the screening process. Table 1 provides the complete search strategy for MEDLINE. Table 1Complete search strategy for Ovid MEDLINE#SearchResults1Non-Muscle Invasive Bladder Neoplasms/5152(non-muscle invasive bladder neoplasm* or non muscle invasive bladder neoplasm* or non-muscle invasive bladder cancer* or nmibc or non-muscle-invasive bladder cancer*).ab,kf,ti.489231 or 248954Administration, Intravesical/49965(intravesical administration* or bladder drug administration* or intravesical drug administration* or intravesical injection* or bladder instillation* or intravesical instillation*).ab,kf,ti.318564 or 565817Mycobacterium bovis/14 3338(mycobacterium bovis or bcg or calmette-guerin bacillus or bacillus calmette guerin).ab,kf,ti.34 35397 or 836 92410Mitomycin/13 01411(mitomycin or mitomycin-c or mitomycin c).ab,kf,ti.19 2591210 or 1122 316146 or 9 or 1262 248153 and 142285 Complete search strategy for Ovid MEDLINE Furthermore, we will manually search the non-indexed scientific journals ‘Urologic Nursing’ and ‘International Journal of Urological Nursing’, as well as Nordic sources in ‘Klinisk sygepleje’ (Clinical Nursing) and ‘Nordisk sygeplejeforskning’ (Nordic Nursing Research) through Idunn.no. PROSPERO will be searched for ongoing or recently completed systematic reviews, and Google Scholar will be searched for grey literature. Additionally, we will include national and international guidelines, sourced online or obtained from national societies. Thirdly, backward snowballing will be carried out by searching the reference lists of all included studies to identify other relevant studies. Forward snowballing will be conducted by citation tracking the ten most relevant papers included in the review to ensure capturing all relevant studies. Selection of sources of evidence All identified citations will be uploaded into the software Covidence, where duplicates will be removed. Titles and abstracts will be screened against the inclusion criteria by two authors independently (LRL, BTJ and SVL). Cases of discrepancy will be solved through discussion until consensus is reached. The full text of potentially relevant sources of evidence will be retrieved and assessed in detail by two or more independent reviewers. Reviewers will meet regularly throughout the screening and selection process to discuss uncertainties, thereby preventing discrepancies. Disagreements will be solved through discussion.33 The identification of evidence sources, screening and selection of included records will be illustrated in a PRISMA flow diagram (figure 1), providing reasons for excluding sources during the full-text review.27 29 PRISMA diagram illustrating the selection process. We will not conduct a critical appraisal of the sources of evidence included in this scoping review, as this aligns with guidelines.28 29 Data charting process Data will be charted from included sources of evidence by two or more reviewers independently by employing a data charting tool provided by Covidence with a customisable structure modified by the authors for the current scoping review. As recommended by Levac et al,34 the data charting tool will initially be pilot tested by all reviewers participating in charting data, completing independent charting of data from five to ten studies. Inconsistencies will be discussed and reflected on against the aim and research question until a consensus is reached, ensuring comprehensive and rigorous data charting. The pilot testing of the data charting tool may be repeated to ensure homogeneity in charting, and necessary adaptations based on the included sources of evidence will be made. Data items The data charting form will include four main data charting categories. The data categories are (1) characteristics of the sources (authors, publication year, country, study design, etc); (2) characteristics of the setting (eg public or private healthcare, rural or urban setting); (3) treatment characteristics (pharmaceutical agent, induction or maintenance, treatment adherence); and (4) data regarding any factors influencing adherence including physical, psychological, social, demographic and socioeconomic factors and reasons for non-adherence. Furthermore, we will record the definition of the primary outcome, which is treatment adherence, as a preliminary literature search indicates that definitions of adherence vary in how delays are handled, whether patients declining treatment are included, and whether authors operate with ‘partial adherence’.13 35 Synthesis of results We expect to include primarily prospective or retrospective cohort studies; however, we will include all relevant literature. We will perform our data synthesis as a narrative synthesis describing how the results inform the research questions and review objective. Varying definitions of treatment adherence will be summarised, and the identified factors influencing treatment adherence will be summarised qualitatively and quantitatively if applicable under relevant headlines reflecting whether they relate to physical, psychological, social, demographic or socioeconomic circumstances. Visuals, such as tables, figures, and an evidence gap map, will be used to present data if considered helpful. However, final decisions on data presentation will be made when the data has been charted and described. Patient and public involvement Patients or public stakeholders have not been involved in the design of this scoping review. However, active involvement of patients and other stakeholders has been established through an advisory group. The group consists of members of the national bladder cancer patient organisation, as well as healthcare professionals providing intravesical instillations from across Denmark, and healthcare professionals in the primary care sector. The advisory group will be informed of the preliminary findings of the review and will support the research team in validating our findings and identifying gaps to be aware of in future research efforts. Ethics and dissemination No ethical approval is required for this scoping review as all data have previously been published in papers or guidelines. The findings will be reported in accordance with the PRISMA guideline for scoping reviews29 in a peer-reviewed scientific journal and at various conferences. Furthermore, the findings will be shared with healthcare professionals, patients and the public via social media, teaching and presentations. Discussion This scoping review will be conducted and reported in accordance with international guidelines28 29 to ensure a systematic and rigorous completion of all steps. It is performed by a team of experienced urological nurse researchers with extended knowledge of bladder cancer care and treatment, as well as methodological expertise in scoping reviews. The breadth of the search strategy, the avoidance of limitations by applying additional search terms and the accounting for time constraints ensure a comprehensive yet feasible search of the relevant literature. A strength is the continuous involvement of stakeholders, including patients, relatives and healthcare professionals across settings, through an affiliated advisory group. Varying definitions of the primary outcome limit the ability to compare studies. However, this scoping review aims to provide a definition and map the evidence instead of comparing results. Based on this review, we will propose a definition of treatment adherence to intravesical instillation therapies to enhance clarity and reduce ambiguity in future scientific communications. By mapping literature on factors influencing treatment adherence, this review will act as a central resource on the topic. It will identify literature gaps that can be explored in future studies as planned in the research project ‘NAVIGATE – Non-Adherence to intraVesical Instillations and Guideline-Advised TreatmEnts’. Findings can help the NAVIGATE research team and others to create interventions to alleviate challenges and support patients throughout their treatment pathways, with the goal of increasing treatment adherence and reducing the impact on patients’ quality of life. Furthermore, knowledge gained through this review may inform healthcare professionals across countries and clinical settings, patient organisations and researchers.